USA – FDA: Include more African Americans in myeloma trials

New guidance that emerged from an FDA and American Association for Cancer Research joint workshop addresses the underrepresentation of African Americans in multiple myeloma clinical trials.

Published in Blood Cancer Discovery, the recommendations are aimed at eliminating racial bias by including more African Americans — who are twice as likely as white individuals to be diagnosed with myeloma — in clinical trials. The recommendations also support using real-world data to better understand the effects of antimyeloma agents among African American patients…